GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crinetics Pharmaceuticals Inc (NAS:CRNX) » Definitions » Operating Margin %

Crinetics Pharmaceuticals (Crinetics Pharmaceuticals) Operating Margin % : -11,488.91% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Crinetics Pharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Crinetics Pharmaceuticals's Operating Income for the three months ended in Mar. 2024 was $-73.53 Mil. Crinetics Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was $0.64 Mil. Therefore, Crinetics Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2024 was -11,488.91%.

The historical rank and industry rank for Crinetics Pharmaceuticals's Operating Margin % or its related term are showing as below:

CRNX' s Operating Margin % Range Over the Past 10 Years
Min: -9990.91   Med: -5547.17   Max: -3544.06
Current: -5547.17


CRNX's Operating Margin % is ranked worse than
87.49% of 1031 companies
in the Biotechnology industry
Industry Median: -169.17 vs CRNX: -5547.17

Crinetics Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Crinetics Pharmaceuticals's Operating Income for the three months ended in Mar. 2024 was $-73.53 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-248.16 Mil.


Crinetics Pharmaceuticals Operating Margin % Historical Data

The historical data trend for Crinetics Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crinetics Pharmaceuticals Operating Margin % Chart

Crinetics Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial - - -9,990.91 -3,544.06 -5,547.17

Crinetics Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,790.89 -5,363.87 -17,045.38 - -11,488.91

Competitive Comparison of Crinetics Pharmaceuticals's Operating Margin %

For the Biotechnology subindustry, Crinetics Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Crinetics Pharmaceuticals's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crinetics Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Crinetics Pharmaceuticals's Operating Margin % falls into.



Crinetics Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Crinetics Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-222.608 / 4.013
=-5,547.17 %

Crinetics Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-73.529 / 0.64
=-11,488.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Crinetics Pharmaceuticals  (NAS:CRNX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Crinetics Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of Crinetics Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Crinetics Pharmaceuticals (Crinetics Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
10222 Barnes Canyon Road, Building No. 2, San Diego, CA, USA, 92121
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Executives
Stephen F. Betz officer: Chief Scientific Officer 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121
Dana Pizzuti officer: Chief Development Officer C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121
Marc Wilson officer: See Remarks 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Richard Scott Struthers director, officer: See Remarks C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Alan Seth Krasner officer: Chief Medical Officer C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Vivaldi Coelho Rogerio director 225 SECOND AVENUE, WALTHAM MA 02451
Jeff E. Knight officer: Chief Operating Officer CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121
Matthew K Fust director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Caren Deardorf director C/O MAGENTA THERAPEUTICS, INC., 100 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
James Hassard officer: Chief Commercial Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Ajay Madan officer: Chief Development Officer C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. 2, SAN DIEGO CA 92121
Camille L Bedrosian director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Vivo Capital Fund Viii, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003